Lymphomas account for 10 percent of childhood malignancies with slightly less than half designated as Hodgkin's disease and the remainder as NonHodgkin's Lymphoma (NHL).
The standard treatment for children with NHL has been radiation therapy until recent times. Low dose chemotherapy was given for systemic relapse, which occurred in the great majority of patients and the prognosis was uniformly poor. Wollner et al. (1976) reported that the use of a modified intensive combination chemotherapy programme initially designed for the treatment of children with acute lymphoblastic leukaemia (ALL), had resulted in a substantial improvement in prognosis for children with NHL. Their results have been confirmed by others using similar treatment programmes.
The role of radiation therapy when combined with such chemotherapy schedules has been the subject of considerable controversy. In such a rare group of diseases, it was clear that a multi-centre trial would be necessary to accrue sufficient numbers of patients for randomised studies and yet in that context it was not thought possible to administer safely both standard radiation and standard combination chemotherapy without compromising one or other modality. The design of one trial (Murphy & Hustu, 1980) (Habeshaw, 1980) . The extent of disease at diagnosis was categorized according to the St Jude staging system (Table I) (Table II) . Marrow aspirate and trephine were required from a minimum of two sites since patchy involvement of marrow is well documented in childhood lymphomas. All patients were evaluated for the extent of their disease with a minimum of a complete history and physical examination, full blood count, bone marrow aspirate and trephine, lumbar puncture with cytocentrifugation of CSF for white cell morphology, and chest X-ray.
The majority of patients with disseminated disease were staged and started on treatment within 48 h of referral. Those patients with apparently localised disease were subjected to a more rigorous staging investigation including, where necessary, lymphangiography, CT scanning and laparotomy. This was regarded as particularly important when the definition of extent of disease determined a significant alteration in the treatment offered, as was the case in this trial for Stage I disease. Stage II for patients with abdominal primaries requires laporotomy and resection of localised disease. Survival and failure-free survival curves were calculated by the life-table method and compared using the logrank test (Peto et al., 1977) .
Failure-free survival (FFS) denotes the period from entry into the study to the occurrence of any adverse event, such as failure to enter complete remission by the end of the induction phase, relapse or death.
The trial protocols
The primary objective for Stage I patients was to determine whether initial treatment should be with radiation alone, or radiation plus short-term combination chemotherapy. Patients therefore received 30 Gy in 3 weeks (2 Gy per fraction, 5 days per week) to the involved field and were randomly assigned to additional COP (Cyclophosphamide, Oncovin, Prednisolone) chemotherapy every 3 weeks for 10 doses, or no further treatment, the first dose of COP being given on day 1 of radiation and the second dose being given on completion (Table  III) .
All other patients were treated with a combination chemotherapy programme (Table IV and Figure 1 ). (Mott et al., 1984) . Forty-eight other patients registered on the study were excluded from the trial for the reasons indicated in Table II . Thus 120 patients were eligible for entry into the NHL trial. There were 97 boys and 23 girls with an age-range from 2-14 years at diagnosis, the male predominance being as expected from all other studies of this disorder in childhood.
Seven This trial confirms that combination chemotherapy should be the primary treatment modality for childhood NHL, and that the majority of such patients should now be long-term survivors. The pilot studies on which this trial was based (Wilson et al, 1977; Goldman et al, 1981) were initiated at the same time as another trial in which patients with advanced disease were randomised to receive or not to receive 30-35 Gy to areas of bulk disease during induction chemotherapy, combined with a more gentle maintenance chemotherapy programme (Murphy & Hustu, 1980) .
The results of that trial showed no benefit to the patients who received radiation at the onset of treatment in higher doses than in this trial. In addition a smaller proportion of patients with disseminated disease survived relapse-free in the long term. Thus neither standard dose radiation given at the time of diagnosis nor low dose radiation given at the time of consolidation appeared to confer any benefit to the patient in these studies. The well documented hazards of second malignant neoplasms occurring in lymphoma patients who have had both chemotherapy and radiotherapy (Donaldson & Kaplan, 1982) , is an additional argument for minimising radiotherapy in patients treated primarily with combination chemotherapy and for giving it only when essential.
Patients whose treatment fails and whose disease progresses usually have systemic relapse, with spread to bone marrow and/or central nervous system or other sanctuary sites. This suggests that the correct strategy for most patients is to intensify chemotherapy rather than to increase treatment to the local area, which would certainly compromise tolerance for further intensive chemotherapy.
The lower rate of relapse in patients with truly localised disease, i.e. Stage I, coupled with the capacity to eradicate disseminated disease in a substantial proportion of patients suggests that a policy of using involved field radiation alone in the first instance might possibly be appropriate for highly selected patients with apparently localised The number of patients required to establish this point makes it impractical to consider further except in the context of an international study. The role of radiotherapy in the overwhelming majority of patients with more advanced disease, is however, clearly called into question.
Of the 42 patients with abdominal primaries, there was failure to control their disease in 13 (Table V) . Two patients died of biochemical problems, hyperkalaemia on day 1, and urate nephropathy on day 9. Two patients developed local regrowth during the induction period and three soon afterwards (2, 2.5, 3, 4.5, 11 months from diagnosis) and they survived 4.5, 5, 6, 6 and 15 months. Clearly the major problem for patients with abdominal lymphoma was failure to control local disease, though systemic spread to CNS and bone marrow despite systemic and intrathecal chemotherapy occurred also. Local radiation appeared to make no difference, whether given during induction, as in the St Jude trial (Murphy & Hustu, 1980) , or during consolidation as in our patients.
There were only 2 relapses later than 12 months which suggests that one year of this type of treatment might be sufficient for this group of patients.
The behaviour of the patients with mediastinal primaries, who nearly all have T cell Lymphoma (Bernard et al., 1982) was different. These patients continued to suffer relapse throughout the two year period of chemotherapy and subsequently on both the NHL and the intensified T cell protocols. The implications for future treatment of T cell disease are discussed in the companion report (Mott et al., 1984) .
It is now well established that the great majority of patients with mediastinal primaries have T cell lymphoma, whereas those with abdominal primaries have B cell lymphoma (Bernard et al., 1982) , so the finding that their responses to the same treatment regimen are different is not particularly surprising. A histological corollary of this is the finding in the CCSG trial that different chemotherapy protocols were effective for lymphoblastic versus other histological categories of non-Hodgkin's lymphoma of childhood (Anderson et al., 1983) .
The toxicity of this treatment programme was variable as might be anticipated from such a complex schedule. Half of the patients required a 15% or greater reduction in chemotherapy at some stage in their programme, and both survival and FFS were substantially better in that group when compared to those not reported to require dose modifications. The same was true for patients on the more intensive T cell protocol (Mott et al., 1984) and the difference for both trials combined is highly significant. The types of toxicity encountered and their relationship to prognosis will be the subject of a separate report.
The success of this treatment regimen for patients with disseminated disease, particularly those without mediastinal primaries, whether or not they received adjuvant radiation, suggests that exposure of these patients to radiation and the attendant foreseeable hazards of combined radiation/chemotherapy is unnecessary in most instances. The fact that all the patients in the CCSG trial were exposed to both radiation and combination chemotherapy, as were half of the patients in our trial, must give rise to some concern that second malignant neoplasms may occur in the survivors (Donaldson & Kaplan, 1977) .
Clear-cut differences in response to treatment are now apparent in a number of subgroups of children with NHL. New treatment strategies based on immunopathological classification, primary site and disease extent are required if results are to be improved further and these will be incorporated in the next generation of trials for these conditions.
